Please
`
`
`
`
`
`pi type a us sign (+)
`
`inside
`
`
`
`this —3*
`
`box
`
`m
`
`Under the Paperwork
`
`Reduction
`
`
`
`Act no persons
`
`Substitute
`
`for
`
`form
`
`1449A/PTO
`
`
`
`
`
`
`
` 1995. of are required to
`
`
`
`(use as many sheets as necessary)
`3
`
`of
`
`Sheet
`
`+
`
`OF
`
`respond
`
`for
`
`PTO/SB/08A (10-96)
`use
`
`through 10/31/99. OM8
`0651-0031
`Aoproved
`Patent and Trademark
`Office:
`U.S.
`DEPARTMENT
`of
`information
`unless
`to
`a
`collection
`Complete
`if Known
`13/456,720
`Application Number
`April 26. 2012
`Filing Date
`First Named inventor GUPTA
`1629
`Group Art Unit
`ANDERSON, James D.
`Examiner Name
`Attorney Docket Number
`FR2009/121
`
`- US CNT ••
`
`
`or
`Name of Patentee
`of Cited Document
`
`of
`
`Lines,
`
`Pages, Columns,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`al.
`al.
`
`U.S. PATEMT DOCUiViEMTS
`Date of Pubiication
`Applicant
`Cited Document
`MM-DD-YYYY
`12-08-1998
`07-10-2007
`04-16-2002
`12-18-2001
`05-14-2002
`08-01-1995
`03-28-2002
`
`BOUCHARD et al.
`DIDIER, et al.
`BOUCHARD, et
`BOUCHARD, et
`BOUCHARD, etai.
`BOBEE, etai.
`BOUCHARD, et
`
`al
`
`U.S. Patent Document
`
`Kind Code^
`(if known)
`
`Number
`5,847,170
`7,241,907
`6,372,780
`6,331,635
`6,387,946
`5,438,072
`2002/0038038
`
`Examiner
`Initials"
`
`Cite
`No.1
`
`Examiner
`Initials*
`
`Cite
`No,1
`
`FOREIGN PATENT DOCUMENTS
`i-oreign Patent Document
`Date of Publication
`or
`Cited Document
`King Code-
`Document
`{if known)
`MM-DD-YYYY
`10-03-1996
`01-05-2000
`03-31-2005
`04-21-2010
`
`Name of Patentee
`Applicant of Cited
`
`BOUCHARD, et
`BOUCHARD, et
`DIDIER, et al.
`CHAUCHEREAU etai.
`
`al.
`al.
`
`Number4
`Office3
`WO 96/30355
`EP 0817779
`WO 2005/028462
`EP 2177630
`
`Pages, Columns,
`of
`Where Relevant
`Passages or Relevant
`
`Lines,
`
`jn
`
`Examiner
`Signature
`
`Date
`Considered
`
`*EXAMlNER: initial if reference
`considered, include copy of
`
`considered,
`this
`form
`
`whether or not
`
`with
`
`citation
`next
`
`is
`
`conformance
`in
`communication
`
`with Draw iine
`
`to
`
`MPEP through citation
`
`
`applicant.
`
`
`
`
`
`609. if not
`
`Documents. U.S. Patent 3 Enter Office that issued
`
`of
`number. 2 See attached Kinds
`
`designation
`1 Unique citation
`
`code (VViPO Standard
`
`ST.3) 4 For Japanese
`patent
`
`documents, the indication of
`the
`year
`of
`number of the
`patent
`
`document. 5 Kind of document
`by
`the
`appropriate
`symbols
`possible. 6 Applicant
`is
`place
`a
`check
`mark
`here
`if
`
`to
`
`the document, the two-letter by
`
`the
`reign
`of
`indicated 6 if
`as
`
`English
`ianguace
`
`
`
`in
`
`conformance
`
`the
`
`on
`
`Burden Hour Statement:
`the amount of
`time
`you
`DO NOT
`"
`1
`
`This
`are
`
`form
`required
`
`" '
`
`is
`
`"
`
`to
`
`estimated Time wili vary depending to take
`
`compiete
`this
`
`
`
`
`
`upon
`
`2.0 the
`
`form
`
`needs hours Any comments of
`
`
`
`should
`
`on
`
`the
`
`" "
`
`^
`
`+
`
`01889
`
`MYLAN - EXHIBIT 1004 (Part 11 of 13)
`
`

`
`Piease
`
`type a
`
`pius
`
`sign
`
`(+)
`
`Under the Paperwork
`
`Reduction
`
`m
`
`Act
`
`inside
`
`this
`
`of
`
`1995.
`
`Substitute
`
`for
`
`form
`
`1449R/PTO
`
`Sheet
`
`(use as many sheets as necessary}
`2
`of
`3
`
`PT0/SB/Q8B (10-96)
`
`through 10/3M99. OMB
`
`0651 -0031
`U.S.
`DEPARTMENT
`
`+
`
`OF
`required
`
`box
`
`use
`for
`Office:
`
`Aoproved
`Patent and Trademark
`are
`no
`persons
`if Known
`Complete
`13/456,720
`Appiscatiors Number
`April 26, 2012
`Fiiiiicj Date
`GUPTA
`First Named Inventor
`1629
`Group Ari Unit
`ANDERSON, James D.
`Examiner Name
`Attorney Docket Number
`FR2009/121 -US-CNT
`
`trxamlner
`initials"
`
`Cite
`No.1
`
`DOCUMENTS
`OTHER PRIOR ART - hiON PATEMT LITERATURE
`
`the
`
`Include name of the author
`(in CAPITAL
`LETTELRS),
`title
`of
`item (book, magazine,
`journal,
`serial,
`symposium,
`catalog, volume-issue number's), etc.),
`
`publisher, city
`and/or
`country
`published.
`
`where
`
`article
`
`
`T2
`
`(when
`date,
`
`
`
`(2002), J. Clin., {2005), Vol. CA
`
`
`
`55,
`
`
`
`Cancer pp.
`
`74-108
`
`PARKIN, et a!., Global
`
`Cancer
`
`Statistics,
`
`HtLLERSTED I, et al., The Current State
`Vol 52, pp. 154-179
`
`of
`
`
`
`
`
`J. Hormonal Prostate Cancer, CA Cancer Therapy for Clin.,(2002),
`
`
`
`
`
`
`
`HORWITZ et a!.,
`pp. 349-375
`
`txternal
`
`
`
`Beam Radiation I herapy for Prostate Cancer, CA
`
`
`Cancer J. Clin., (2000); Vol. 50,
`'
`
`PIENTA et a!., Advances
`Vol. 55, pp. 300-318,
`
`in
`
`Prostate
`
`Cancer
`
`Chemotherapy: Begins. CA Cancer
`
`'
`
`J.
`
`
`
`A Clin,
`
`
`
`New (2005),
`
`CABRAL, Factors Determining
`4
`Updates, (2001), Vol. pp.
`3-8
`No.
`
`
`Cellular
`1
`^
`
`Mechanisms
`
`of
`
`Resistance Resistance
`
`"
`
`to
`
`Dynamics,
`Vol.
`
`17,
`
`to DUMONTE I, et al., Mechanisms of Action of and Resistance Antitubulin Agents: Microtubule
`
`
`
`Drug Transport and
`Cell
`Death,
`J.
`
`One., Clin. No. 3, pp. 1061-1070
`(1999),
`
`al.,
`HALEBLIAN, et
`Applications, J. Pharm,
`
`Characterization
`Sci.,
`(1975),
`
`of
`pp.
`
`Habits
`1269-1288
`
`and
`
`Crystalline
`
`Modification
`
`MELZACK, The McGill
`277-299
`
`Pain
`
`Questionnaire:
`'
`
`Major
`"
`
`Properties
`
`And
`
`'
`
`Scoring
`
`BERRY, et a!., Quality
`Group Randomized
`Trial
`Clinical Oncology,
`(2006),
`
`of
`
`
`
`
`
`Life in Advanced Stage and Pain Prostate Cancer:
`Comparing
`Docetaxel
`and
`Vol.
`
`No. 24, 18, pp. 2828-2835
`
`
`Results
`
`
`of
`Estramustine Journal of
`
`a
`to
`
`Southwest
`Mitoxantrone
`
`FIZAZ, etal.,
`
`New
`
`agents
`
`in
`
`Metastatic Prostate Cancer,
`
`
`
`J. Cancer. Eur. 45, Supp. 1 pp. 379-380
`
`
`
`
`
`2009,
`
`Examiner
`Signature
`
`Date
`Considered
`
`
`
`DOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOi) '
`
`considered,
`*EXAMiNER: initial if reference
`considered, include copy of
`this
`form
`
`whether
`with
`
`next
`
`or
`
`not
`communication
`
`
`citation 609, Draw iine
`to
`
`citation
`is through
`
`applicant.
`
`if
`
`not
`
`in
`
`in
`
`
`
`conformance conformance
`
`Unique citation
`
`designation
`
`
`
`number. 2 Applicant
`
`is
`
`to place a check mark
`
`here
`
`if
`
`English
`
`language
`
`Translation
`
`is
`
`Burden Hour Statement:
`the amount of
`time
`you
`
`This
`are
`
`is 2.0 hours
`
`form
`required
`
`estimated to complete, to i ime wiil vary depending take
`
`
`
`
`to
`complete
`this information Officer,
`
`
`upon
`Patent
`
`the
`
`form and
`
`on
`needs Any comments of
`
`
`should
`Office.
`Trademark
`
`the
`
`/JDA/
`
`+ DO NOT
`
`01890
`
`

`
`Piease
`
`type a
`
`pius
`
`sign
`
`(+)
`
`Under the Paperwork
`
`Reduction
`
`m
`
`Act
`
`of
`
`inside
`
`Substitute
`
`for
`
`form
`
`1449R/PTO
`
`Sheet
`
`sheets
`(use as many
`3
`of
`
`as
`3
`
`PT0/SB/Q8B (10-96)
`10/3M99. OMB 0651 -0031
`through
`U.S.
`DEPARTMENT
`
`+
`
`OF
`required
`
`this
`
`box
`
`1995.
`
`use
`for
`Office:
`
`Aoproved
`Patent and Trademark
`are
`no
`persons
`if Known
`Complete
`13/456,720
`Appiscatiors Number
`April 26, 2012
`Fiiiiicj Date
`GUPTA
`Inventor
`First Named
`1629
`Group Ari Unit
`ANDERSON, James D.
`Examiner Name
`necessary}
`Attorney Docket Number
`FR2009/121 -US-CNT
`
`trxamlner
`initials"
`
`Cite
`No.1
`
`DOCUMENTS
`OTHER PRIOR ART - hiON PATEMT LITERATURE
`
`the
`
`Include name of the author
`(in CAPITAL
`LETTELRS),
`title
`of
`item (book, magazine,
`journal,
`serial,
`symposium,
`catalog, volume-issue number's), etc.),
`
`publisher, city
`and/or
`country
`published.
`
`where
`
`article
`
`
`T2
`
`(when
`date,
`
`http://ciinicaltriais.gov/archive/NCT0Q417079/20Q6_12_28,
`Plus Predinisone Compared
`to
`
`Miitoxantrone Predisone
`Cancer (TROPIC). Retrieved on 02/08/2012
`
`View
`
`Plus in Hormaone
`
`of
`Refractory
`
`NCT0Q417079 2006_12_28
`
`Metastatic Prostate
`
`or?
`
`Plus de BONO, et a!., Prednisone Cabazltaxel or Mitoxantrone
`
`
`Cancer Progressing
`after
`Docetaxel
`Treatment:
`(2010), pp. 1147-1154
`
`'
`
`for
`a
`
`Castration-Resistant
`Metastatic
`
`Randomised Vol. 376, No. 9747, Ooen-Labei
`
`
`GALSKY, et a!., Cabazitaxei,
`
`Nature
`
`Reviews-
`
`Drug
`
`Discovery, Vol.
`
`9,
`
`International Search
`
`Report
`
`for
`
`WO2011/051894
`
`dated
`
`May
`
`5,
`
`2011
`
`Jevtana Prescribing
`
`
`
`
`
`pp. Information, 1-25, June 17, 2010
`
`Examiner
`Signature
`
`/James Anderson/
`
`Date
`Considered
`
`09/10/2013
`
`DOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOi)
`'
`
`considered,
`*EXAMiNER: initial if reference
`considered, include copy of
`this
`form
`
`whether
`with
`
`next
`
`or
`
`not
`communication
`
`
`citation 609, Draw iine
`to
`
`citation
`is through
`
`applicant.
`
`if
`
`not
`
`in
`
`in
`
`
`
`conformance conformance
`
`Unique citation
`
`designation
`
`
`
`number. 2 Applicant
`
`is
`
`to place a check mark
`
`here
`
`if
`
`English
`
`language
`
`Translation
`
`is
`
`+ DO NOT
`
`Burden Hour Statement:
`the amount of
`time
`you
`
`This
`are
`
`is 2.0 hours
`
`form
`required
`
`estimated to complete, to i ime wiil vary depending take
`
`
`
`
`to
`complete
`this information Officer,
`
`
`upon
`Patent
`
`the
`
`form and
`
`on
`of Any comments
`
`needs
`should
`Office.
`Trademark
`
`the
`
`/JDA/
`
`01891
`
`

`
`OK TO ENTER: /JDA/
`
`09/10/2013
`
`Sisr-of! Rs: No. FR2i;09/121
`
`US
`
`CN'F
`
`Amendment Pursuant
`In the Specification:
`
`to 37
`
`
`
`C.F.R. 1.121 S
`
`
`
`Please replace the paragraph beginning at page 7,
`specification with the following rewritten paragraph:
`
`line 1 of
`
`the
`
`Cabazitaxel may be administered in base form (cf. above formula), or in the form of a
`hydrate. It may
`
`be also a solvate, i.e. a molecular
`
`complex
`
`characterized the incorporation
`of the crystallization
`
`solvent into the crystal of
`the molecule
`of
`
`the in this
`respect page 1276 of J. Pharm. Sci. 1975, 54(8), 1269-1288). In particular, it may be an
`acetone solvate, and, more particularly, may be the solvate described in WO 2005/028462
`2005/02846. It may be an acetone solvate
`
`of cabazitaxel containing between 5% and 8% and
`preferably between
`5%
`
`7% and by weight of
`
`acetone
`
`(% means content of acetone/content of
`100). An average value of the acetone content is 7%, which
`acetone+cabazitaxel
`approximately represents the acetone stoichiomctry, which is 6.5% for a solvate containing
`one molecule of
`acetone.
`The
`procedure
`
`
`
`described allows the preparation below an acetone of
`
`solvate of cabazitaxel:
`
`by
`active
`
`01892
`
`

`
`Connecting via Winsock to
`
`
`
`STN at pto-stn port 23 on
`
`
`
`Welcome to STN International! Enter x:X
`LOGINID:SSPTAJDA1614
`PASSWORD:
`TERMINAL (ENTER 1, 2, 3, OR ?):2
`
`available
`
`NEWS 1 FEB 1
`MAY 23
`NEWS 2
`NEWS 3
`DEC 10
`NEWS 4
`JAN 17
`
`Welcome to STN International
`options
`Instructor-led and on-demand STN training
`from CAS
`
`Get the Latest Version of STN Express, Version 8.5.1!
`STN
`on
`New SDI STANDARD Option Streamlines
`SDI Set-ups
`Cooperative Patent Classification (CPC) Search and Display
`Capabilities Now Available in CA/CAplus Family
`of
`Databases
`and USPAT Databases on STN
`JAN 23
`NEWS 5
`INPADOC: CPC Backfile Data Now Available
`JAN 2 8
`NEWS 6
`Reloaded MEDLINE on STN
`
`Now Includes 2013 MeSH Vocabulary and New Fields
`JAN 31
`NEWS 7
`Expiration
`INPADOC Databases Enhanced with Calculated
`INPADOC Enhanced with Citing Patent
`Information
`JAN 31
`NEWS 8
`INPAFAMDB Enhanced with Patent Family
`Counts
`JAN 31
`NEWS 9
`Enhancements to COMPENDEX
`FEB 6
`NEWS 10
`2013 MARPAT Backfile Expansion Update
`FEB 22
`NEWS 11
`New
`Derwent World Patents Index (DWPI)
`MAR 06
`Indonesia
`NEWS 12
`Coverage
`MAR 11
`JAPIO Will No Longer Be Updated from
`NEWS 13
`March
`2013
`MAR 22
`NEWS 14
`Cooperative Patent Classification
`
`(CPC) Added to USPATOLD
`on STN
`NEWS 15
`MAR 25
`
`SciSearch on STN Now Includes New Fields
`Find Grant Information More Easily
`APR 29
`NEWS 16
`Emtree Thesaurus Updated in Embase
`APR 29
`NEWS 17
`Embase Alert (EMBAL) Enhanced with Articles-in-Press Content
`
`
`a and Optimized for Use as Companion Database for Embase
`NEWS 18 APR 30
`Derwent WPI: The New Cooperative Patent Classification Is
`Now Available
`NEWS 19
`MAY 21
`STN Updated to Reflect Streamlining of CAS Roles
`NEWS 2 0
`MAY 24
`
`CABA Has Been Reloaded on May 24, 2 013
`NEWS 21
`MAY 28
`STN Adds Indian Patent Full Text File INFULL
`
`NEWS 22
`JUL 09
`TULSA and TULSA2 were reloaded on July 8, 2013
`NEWS 23
`JUL 15
`
`New IFIALL Database on STN Increases US Patent Retrieval
`Capabilities
`NEWS 2 4 JUL 24
`Find the Most Comprehensive and Timely Results When Searching
`the Newly Enhanced Embase Alert(TM) together with Embase(TM)
`NEWS 25 JUL 31
`New PV Cluster on STN(R) Simplifies Pharmacovigilance
`Alerting and Searching
`NEWS 26
`AUG 09
`
`DWPI Manual Code Revision submit your suggestions
`NEWS 27
`AUG 15
`PCTFULL documents with Chinese, Japanese, or Korean as
`
`filing language have English machine translations
`NEWS 28 AUG 16
`The 2013 Inventory of Existing Chemical
`Substances
`is Now Available on STN
`NEWS 29 SEP 10
`CAS Expands Coverage of Philippines Patents
`
`NEWS EXPRESS 23 MAY 2012 CURRENT WINDOWS VERSION IS V8.5.1,
`AND CURRENT DISCOVER FILE IS DATED 22 JULY 2013.
`
`Dates
`
`Onwards
`
`in
`
`China
`
`01893
`
`

`
`NEWS HOURS
`Desk Availability
`STN Operating Hours Plus Help
`NEWS LOGIN
`Welcome Banner and News Items
`NEWS TRAINING Find instructor-led and self-directed
`training opportunities
`Enter NEWS followed by the item number or name to
`see
`news
`on that
`specific topic.
`STN
`the
`of
`provisions
`the
`All use of STN is subject to
`agreement.
`
`research. Use
`scientific
`This agreement limits use to
`
`for software development or design, implementation of commercial
`gateways,
`or use of CAS and STN data in the
`
`building of commercial
`products is prohibited and may result in loss of user privileges
`and other penalties.
`
`customer
`
`TOTAL
`SESSION
`0.24
`
`data
`
`file
`
`STN Columbus
`FILE 'HOME' ENTERED AT 10:55:45 ON 10 SEP 2013
`=> fil reg
`SINCE FILE
`COST IN U.S. DOLLARS
`ENTRY
`FULL ESTIMATED COST
`0.24
`10 SEP
`2013
`ON
`FILE 'REGISTRY' ENTERED AT 10:55:54
`
`USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
`PLEASE SEE "HELP USAGETERMS" FOR
`DETAILS.
`COPYRIGHT (C) 2013 American Chemical
`Society
`(ACS)
`Property values tagged with IC are
`from
`the
`ZIC/VINITI
`provided by InfoChem.
`9 SEP 2013
`STRUCTURE FILE UPDATES:
`HIGHEST RN 1450791-93-1
`DICTIONARY FILE UPDATES:
`HIGHEST RN 1450791-93-1
`9 SEP 2013
`CAS Information Use Policies apply and are
`available
`http://www.cas.org/legal/infopolicy
`
`TSCA INFORMATION NOW CURRENT THROUGH
`JANUARY 013
`4, 2
`Please note that search-term pricing does
`apply
`conducting SmartSELECT searches.
`experimental
`for
`data
`REGISTRY includes numerically searchable
`availability
`indicating
`predicted properties as well as
`tags
`experimental property data in the
`original
`
`document, For information
`on property searching in REGISTRY, refer
`to:
`http://www.cas.org/training/stn/database-specific
`=> s cabazitaxel/cn
`LI
`1 CABAZITAXEL/CN
`=> d 11
`ANSWER 1 OF 1 REGISTRY COPYRIGHT 2013 ACS on STN
`L1
`RN
`183133-96-2 REGISTRY
`ED
`Entered STN: 14 Nov 1996
`Benzenepropanoic acid, p-[[(1,1-dimethylethoxy)carbonyl]amino]-
`CN
`a-hydroxy-, (2aR,4S,4aS,6R,9S,IIS,12S,12aR,12bS)-12b-(acetyloxy)-12-
`(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-ll-hydroxy-4, 6
`dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-lH-
`
`at:
`
`when
`
`and
`of
`
`01894
`
`

`
`(CA INDEX
`
`cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,pS)
`NAME)
`OTHER CA INDEX NAMES:
`Benzenepropanoic acid, p-[[(1,1-dimethylethoxy)carbonyl]amino]-
`CN
`a-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-
`2a, 3, 4, 4a, 5,6,9,10,11,12,12a, 12b-dodecahydro-ll-hydroxy-4,6-dimethoxy-
`4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-lH-cyclodeca[3,4]benz[1,2-b]oxet-
`9-yl ester, [2aR-[2aa,4p,4aP,6P,9a(aR*,.b
`eta.S*),11a,12a,12aa,12ba]]-
`OTHER NAMES:
`Cabazitaxel
`CN
`CN
`TXD 258
`XRP 6258
`CN
`STEREOSEARCH
`FS
`890654-44-1
`DR
`C45 H57 N 014
`MF
`CI COM
`SR CA
`LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS,
`CHEMLIST, EMBASE, IMSPATENTS, IMSRESEARCH,
`USPATFULL
`Absolute stereochemistry. Rotation (-).
`
`CBNB,
`CASREACT,
`IPA,
`TOXCENTER,
`
`CHEMCATS,
`USAN,
`USPAT2,
`
`t-BuO
`
`H
`N. S
`
`OH
`
`R
`
`0
`
`Ph
`
`0
`
`MeO
`
`Me
`
`0,
`
`S Me-
`S,
`
`OH
`
`0:
`
`OMe
`R
`S, S
`Me
`Me
`R
`R
`S
`H
`AcO
`
`0
`
`S
`
`0
`
`" H
`0
`
`Ph
`
`**PROPERTY DATA AVAILABLE IN THE
`FORMAT**
`'PROP'
`225 REFERENCES IN FILE CA
`
`(1907 TO DATE)
`7 REFERENCES TO NON-SPECIFIC DERIVATIVES
`228 REFERENCES IN FILE CAPLUS (1907
`TO
`
`IN FILE
`DATE)
`
`CA
`
`=> s 183133-96-2/crn
`13 183133-96-2/CRN
`L2
`=> s 11 or 12
`14 LI OR L2
`L3
`=> select chem 13 1-
`E1 THROUGH E20 ASSIGNED
`=> d sel el-e20
`El
`1
`E2
`1
`
`CABAZITAXEL HYDRATE/BI
`CABAZITAXEL/BI
`
`01895
`
`

`
`E3
`E4
`E5
`E6
`E7
`E8
`E9
`E10
`Ell
`E12
`E13
`El 4
`E15
`E16
`El 7
`El 8
`E19
`E20
`
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`
`INDEX NAME NOT YET ASSIGNED/BI
`TXD 258/BI
`XRP 6258/BI
`1345729-91-0/BI
`1393818-87-5/BI
`1402820-62-5/BI
`1402820-63-6/BI
`1402820-64-7/BI
`1402820-65-8/BI
`1402820-68-1/BI
`1426815-65-7/BI
`1426815-66-8/BI
`1426815-67-9/BI
`1430721-70-2/BI
`1438897-79-0/BI
`1443430-50-9/BI
`183133-96-2/BI
`890654-44-1/BI
`
`=> que el-e20
`"CABAZITAXEL HYDRATE"/BI
`(("CABAZITAXEL"(W)"HYDRATE")/BI)
`"INDEX NAME NOT YET ASSIGNED"/BI
`(("INDEX"(W)"NAME"(W)"NOT"(W)"YET"(W)"ASSIGNED")/BI)
`"TXD 258"/BI
`(("TXD"(W)"258")/BI)
`"XRP 6258"/BI
`(("XRP"(W)"6258")/BI)
`1345729-91-0/BI
`(1345729-91-0/RN)
`1393818-87-5/BI
`(1393818-87-5/RN)
`1402820-62-5/BI
`(1402820-62-5/RN)
`1402820-63-6/BI
`(1402820-63-6/RN)
`1402820-64-7/BI
`(1402820-64-7/RN)
`1402820-65-8/BI
`(1402820-65-8/RN)
`1402820-68-1/BI
`(1402820-68-1/RN)
`1426815-65-7/BI
`(1426815-65-7/RN)
`1426815-66-8/BI
`(1426815-66-8/RN)
`1426815-67-9/BI
`(1426815-67-9/RN)
`1430721-70-2/BI
`(1430721-70-2/RN)
`1438897-79-0/BI
`(1438897-79-0/RN)
`1443430-50-9/BI
`(1443430-50-9/RN)
`183133-96-2/BI
`(183133-96-2/RN)
`890654-44-1/BI
`(890654-44-1/RN)
`QUE ("CABAZITAXEL HYDRATE"/BI OR CABAZITAXEL/BI
`NOT
`NAME
`"INDEX
`OR
`IGNED"/BI OR "TXD 258"/BI OR "XRP 6258"/BI OR 1345729-91-0/BI OR 13938
`18-87-5/BI OR 1402820-62-5/BI OR 1402820-63-6/BI
`OR
`1402820-64-7/BI
`
`L4
`
`OR
`
`01896
`
`

`
`OR
`1402820-65-8/BI OR 1402820-68-1/BI OR 1426815-65-7/BI
`/BI OR 1426815-67-9/BI OR 1430721-70-2/BI
`OR
`1438897-79-0/BI
`0-50-9/BI OR 183133-96-2/BI OR 890654-44-1/BI)
`=> file hcaplus; del sel y
`SINCE FILE
`COST IN U.S. DOLLARS
`ENTRY
`14.99
`FULL ESTIMATED COST
`2013
`ON 10 SEP
`FILE 'HCAPLUS' ENTERED AT 10:56:37
`
`USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
`PLEASE SEE "HELP USAGETERMS" FOR
`DETAILS.
`COPYRIGHT (C) 2013 AMERICAN CHEMICAL SOCIETY
`(ACS)
`
`TOTAL
`SESSION
`15.23
`
`1426815-66-8
`OR
`144343
`
`December
`
`is
`
`in this records database refer is
`
`
`which
`Copyright of the articles to
`held by the publishers listed in the PUBLISHER (PB) field (available
`for records published or updated in Chemical Abstracts
`after
`26, 1996), unless otherwise indicated in the original publications.
`the
`The CA Lexicon is the copyrighted intellectual
`property
`of
`American Chemical Society and is
`provided
`to
`
`assist in searching you
`
`databases on STN.
`Any dissemination, distribution, copying,
`or storing
`of this information, without the
`prior
`written
`consent
`of
`CAS,
`strictly prohibited.
`FILE COVERS 1907 10 Sep 2013 VOL 159 ISS 12
`FILE LAST UPDATED: 9 Sep 2013 (20130909/ED)
`REVISED CLASS FIELDS (/NCL) LAST RELOADED: July 2013
`DATE: July 2013
`
`USPTO MANUAL OF CLASSIFICATIONS THESAURUS
`ISSUE
`
`Classification (IPC)
`HCAplus includes complete International
`Patent
`of
`2013.
`reclassification data for the
`third
`quarter
`
`HCAplus now includes the comprehensive Cooperative Patent Classification
`(CPC).
`See HELP CPC for details.
`CAS Information Use Policies apply and are
`http://www.cas.org/legal/infopolicy
`This file contains CAS Registry Numbers
`substance identification.
`
`available
`
`at:
`
`for
`
`easy
`
`and
`
`accurate
`
`or curi?
`
`or
`
`
`
`or => s 14(L)((pac or pkt or dma bac or thu)/rl or (treat? or cure?
`?therap? or pharm? or ?drug))
`241 "CABAZITAXEL"/BI
`123044 "HYDRATE"/BI
`39684 "HYDRATES'VBI
`143084 "HYDRATE"/BI
`(("HYDRATE" OR "HYDRATES")/BI)
`1 "CABAZITAXEL HYDRATE"/BI
`(("CABAZITAXEL"(W)"HYDRATE")/BI)
`241 CABAZITAXEL/BI
`895023 "INDEX"/BI
`156827 "INDEXES"/BI
`14436 "INDICES"/BI
`2 "INDICESES"/BI
`1009192 "INDEX"/BI
`(("INDEX" OR "INDEXES" OR "INDICES" OR "INDICESES")/BI)
`
`01897
`
`

`
`52511 "NAME"/BI
`11016 "NAMES"/BI
`61712 "NAME"/BI
`(("NAME" OR "NAMES")/BI)
`0 "NOT"/BI
`66 "NOTS"/BI
`66 "NOT"/BI
`(("NOT" OR "NOTS")/BI)
`241838 "YET"/BI
`181464 "ASSIGNED"/BI
`0 "INDEX NAME NOT YET ASSIGNED"/BI
`(("INDEX"(W)"NAME"(W)"NOT"(W)"YET"(W)"ASSIGNED")/BI)
`60 "TXD"/BI
`1 "TXDS"/BI
`61 "TXD"/BI
`(("TXD" OR "TXDS")/BI)
`19795 "258"/BI
`6 "TXD 258"/BI
`(("TXD"(W)"258")/BI)
`88 "XRP"/BI
`7 "XRPS"/BI
`91 "XRP"/BI
`(("XRP" OR "XRPS")/BI)
`224 "6258"/BI
`4 "XRP 6258"/BI
`(("XRP"(W)"6258")/BI)
`1 1345729-91-0/BI
`2 1393818-87-5/BI
`3 1402820-62-5/BI
`1 1402820-63-6/BI
`1 1402820-64-7/BI
`1 1402820-65-8/BI
`1 1402820-68-1/BI
`2 1426815-65-7/BI
`1 1426815-66-8/BI
`1 1426815-67-9/BI
`2 1430721-70-2/BI
`1 1438897-79-0/BI
`1 1443430-50-9/BI
`228 183133-96-2/BI
`0 890654-44-1/BI
`892610 PAC/RL
`100824 PKT/RL
`892610 DMA/RL
`(PAC/RL)
`1019432 BAC/RL
`1760886 THU/RL
`5124530 TREAT?
`208290 CURE?
`273923 CURI?
`1157026 ?THERAP?
`9 ?THREAP?
`9 ?THREAP?
`1157030 ?THERAP?
`(7THERAP? OR ?THREAP?)
`1202144 PHARM?
`1275123 ?DRUG
`245 L4(L)((PAC OR PKT OR DMA OR BAC OR THU)/RL OR
`(TREAT? OR CURE?
`OR CURI? OR ?THERAP? OR PHARM? OR ?DRUG))
`=> s 15 and (?neoplas? or ?cancer? or ?tumo? or onco? or carcin? or
`860331 7NEOPLAS?
`
`L5
`
`?sarcoma?)
`
`01898
`
`

`
`730108 7CANCER?
`1065907 7TUMO?
`126740 ONCO?
`449714 CARCIN?
`75 0 42 ?SARCOMA?
`
`?SARCOMA?)
`
`206 L5 AND (7NEOPLAS? OR 7CANCER? OR 7TUMO? OR ONCO? OR CARCIN? OR
`
`L6
`
`
`
`or => s 16 and (ad<20101020 or pd<20101020 prd<20101020)
`
`
`7759426 AD<20101020
`(AD<2 0101020)
`33404260 PD<20101020
`(PD<2 0101020)
`7255525 PRD<20101020
`(PRD<20101020)
`42 L6 AND (AD<20101020 OR PD<20101020
`L7
`=> file biosis
`COST IN U.S. DOLLARS
`FULL ESTIMATED COST
`FILE 'BIOSIS' ENTERED AT 10:58:50 ON 10 SEP 2013
`
`Copyright (c) 2013 The Thomson Corporation
`FILE COVERS 1926 TO DATE.
`CAS REGISTRY NUMBERS AND CHEMICAL NAMES
`FROM JANUARY 1926 TO DATE.
`RECORDS LAST ADDED: 4 September 2013 (20130904/ED)
`
`BIOSIS has been augmented with 1.8 million archival records from 1926
`through 1968.
`These records have been re-indexed to
`match
`current
`BIOSIS indexing.
`=> s 14 and (?neoplas? or ?cancer?
`125 "CABAZITAXEL"/BI
`10234 "HYDRATE"/BI
`1863 "HYDRATES'VBI
`11664 "HYDRATE"/BI
`(("HYDRATE" OR "HYDRATES")/BI)
`0 "CABAZITAXEL HYDRATE"/BI
`(("CABAZITAXEL"(W)"HYDRATE")/BI)
`125 CABAZITAXEL/BI
`473453 "INDEX"/BI
`25122 "INDEXES'VBI
`114676 "INDICES"/BI
`570927 "INDEX"/BI
`(("INDEX" OR "INDEXES" OR "INDICES")/BI)
`12492209 "NAME"/BI
`2 858 4 "NAMES"/BI
`12498582 "NAME"/BI
`(("NAME" OR "NAMES")/BI)
`60 "NOT"/BI
`44 "NOTS"/BI
`104 "NOT"/BI
`(("NOT" OR "NOTS")/BI)
`225538 "YET"/BI
`1 "YETS'VBI
`225539 "YET"/BI
`
`OR PRD<20101020)
`
`SINCE FILE
`ENTRY
`12 . 48
`
`TOTAL
`SESSION
`27.71
`
`
`
`(CNs) PRESENT
`
`or ?tumo?
`
`or
`
`onco?
`
`or
`
`carcin?
`
`or
`
`01899
`
`

`
`(("YET" OR "YETS")/BI)
`"ASSIGNED"/BI
`123980
`"INDEX NAME NOT YET ASSIGNED"/BI
`0
`(("INDEX"(W)"NAME"(W)"NOT"(W)"YET"(W)"ASSIGNED")/BI)
`"TXD'VBI
`25
`"258"/BI
`9264
`0
`"TXD 258"/BI
`(("TXD"(W)"258")/BI)
`34
`"XRP'VBI
`3
`"XRPS"/BI
`35
`"XRP'VBI
`(("XRP" OR "XRPS")/BI)
`272
`"6258"/BI
`0
`"XRP 6258"/BI
`(("XRP"(W)"6258")/BI)
`1345729-91-0/BI
`0
`1393818-87-5/BI
`0
`1402820-62-5/BI
`0
`0
`1402820-63-6/BI
`0
`1402820-64-7/BI
`0
`1402820-65-8/BI
`0
`1402820-68-1/BI
`0
`1426815-65-7/BI
`0
`1426815-66-8/BI
`1426815-67-9/BI
`0
`1430721-70-2/BI
`0
`1438897-79-0/BI
`0
`1443430-50-9/BI
`0
`183133-96-2/BI
`1
`890654-44-1/BI
`0
`1497805
`7NEOPLAS?
`998541
`7CANCER?
`1513504
`7TUMO?
`1538523
`ONCO?
`706287
`CARCIN?
`137898
`?SARCOMA?
`L4 AND (7NEOPLAS? OR ?CANCER? OR ?TUMO?
`125
`?SARCOMA?)
`=> s 18 and py<2011
`21028955 PY<2011
`10 L8 AND PY<2011
`L9
`=> file medline; del sel y
`SINCE FILE
`COST IN U.S. DOLLARS
`ENTRY
`1. 05
`FULL ESTIMATED COST
`2013
`FILE 'MEDLINE' ENTERED AT 10:59:12 ON 10 SEP
`FILE COVERS 19 46 TO DATE.
`FILE LAST UPDATED: 7 Sep 2013 (20130907/UP).
`MEDLINE(R) is a registered trademark of the
`U.S.
`National
`Medicine (NLM).
`available.
`The 2013 MeSH Thesaurus is now
`The 2013 Medline reload was completed
`
`See HELP RLOAD for details.
`This file contains CAS Registry Numbers
`substance identification.
`
`on January 2013.
`
`26,
`
`for
`
`easy
`
`and
`
`accurate
`
`L8
`
`OR
`
`ONCO?
`
`TOTAL
`SESSION
`28 . 76
`
`OR
`
`CARCIN?
`
`Library
`
`of
`
`01900
`
`

`
`or
`
`carcin?
`
`or
`
`
`
`See HELP RANGE before carrying out any RANGE search.
`
`or ?tumo?
`
`or
`
`onco?
`
`=> s 14 and (?neoplas? or ?cancer?
`237 "CABAZITAXEL'VBI
`7318 "HYDRATE'VBI
`1236 "HYDRATES'VBI
`8055 "HYDRATE'VBI
`(("HYDRATE" OR "HYDRATES")/BI)
`0 "CABAZITAXEL HYDRATE'VBI
`(("CABAZITAXEL"(W)"HYDRATE")/BI)
`237 CABAZITAXEL/BI
`613768 "INDEX"/BI
`25143 "INDEXES'VBI
`108630 "INDICES"/BI
`710363 "INDEX"/BI
`(("INDEX" OR "INDEXES" OR "INDICES")/BI)
`40823 "NAME'VBI
`12732 "NAMES"/BI
`51133 "NAME'VBI
`(("NAME" OR "NAMES")/BI)
`4765676 "NOT'VBI
`88 "NOTS'VBI
`4765732 "NOT'VBI
`(("NOT" OR "NOTS")/BI)
`277128 "YET"/BI
`146649 "ASSIGNED"/BI
`0 "INDEX NAME NOT YET ASSIGNED"/BI
`(("INDEX"(W)"NAME"(W)"NOT"(W)"YET"(W)"ASSIGNED")/BI)
`16 "TXD'VBI
`12342 "258"/BI
`1 "TXD 258"/BI
`(("TXD"(W)"258")/BI)
`29 "XRP'VBI
`1 "XRPS'VBI
`29 "XRP'VBI
`(("XRP" OR "XRPS")/BI)
`116 "6258"/BI
`1 "XRP 6258"/BI
`(("XRP"(W)"6258")/BI)
`0 1345729-91-0/BI
`0 1393818-87-5/BI
`0 1402820-62-5/BI
`0 1402820-63-6/BI
`0 1402820-64-7/BI
`0 1402820-65-8/BI
`0 1402820-68-1/BI
`0 1426815-65-7/BI
`0 1426815-66-8/BI
`0 1426815-67-9/BI
`0 1430721-70-2/BI
`0 1438897-79-0/BI
`0 1443430-50-9/BI
`0 183133-96-2/BI
`0 890654-44-1/BI
`2230607 7NEOPLAS?
`1077631 7CANCER?
`1443414 7TUMO?
`325027 ONCO?
`737004 CARCIN?
`
`01901
`
`

`
`LI 0
`
`
`
`OR 236 L4 AND (7NEOPLAS? OR 7CANCER? OR 7TUMO? ONCO? OR CARCIN? OR
`
`SINCE FILE
`ENTRY
`0 . 45
`
`TOTAL
`SESSION
`29.21
`
`162 414 ?SARCOMA?
`
`?SARCOMA?)
`=> s 110 and py<2011
`20256137 PY<2011
`22 LI0 AND PY<2011
`LI 1
`=> file embase; del sel y
`COST IN U.S. DOLLARS
`FULL ESTIMATED COST
`FILE 'EMBASE' ENTERED AT 10:59:26 ON 10 SEP 2013
`
`Copyright (c) 2013 Elsevier B.V.
`All
`
`rights reserved.
`10 Sep
`2013
`Embase-originated material 1947 FILE COVERS:
`
`to
`(20130910/ED)
`Unique MEDLINE content 1948 to
`present
`2013
`1,
`Emtree thesaurus last updated September
`This file contains CAS Registry Numbers
`for
`easy
`and
`substance identification.
`Alert
`in Embase
`content
`Effective July 28, 2013, the
`that in Embase
`is strictly complementary to
`
`(EMBASE). EMBAL
`contains, at any given time, approximately
`100,000
`novel
`records not yet available in Embase. Search both databases
`for the most timely and comprehensive
`
`results. See NEWS for
`details.
`
`accurate
`
`(EMBAL)
`
`or
`
`carcin?
`
`or
`
`or ?tumo?
`
`or
`
`onco?
`
`=> s 14 and (?neoplas? or ?cancer?
`665 "CABAZITAXEL"/BI
`12117 "HYDRATE"/BI
`1314 "HYDRATES'VBI
`12992 "HYDRATE"/BI
`(("HYDRATE" OR "HYDRATES")/BI)
`0 "CABAZITAXEL HYDRATE"/BI
`(("CABAZITAXEL"(W)"HYDRATE")/BI)
`665 CABAZITAXEL/BI
`592770 "INDEX"/BI
`33000 "INDEXES'VBI
`128445 "INDICES"/BI
`709919 "INDEX"/BI
`(("INDEX" OR "INDEXES" OR " INDICES")/BI)
`52846 "NAME"/BI
`14967 "NAMES"/BI
`65247 "NAME"/BI
`(("NAME" OR "NAMES")/BI)
`6268645 "NOT"/BI
`103 "NOTS"/BI
`6268708 "NOT"/BI
`(("NOT" OR "NOTS")/BI)
`364816 "YET"/BI
`5 "YETS'VBI
`364821 "YET"/BI
`(("YET" OR "YETS")/BI)
`173839 "ASSIGNED"/BI
`0 "INDEX NAME NOT YET ASSIGNED"/BI
`(("INDEX"(W)"NAME"(W)"NOT"(W)"YET"(W)"ASSIGNED")/BI)
`42 "TXD"/BI
`
`01902
`
`

`
`"258"/BI
`13281
`"TXD 258"/BI
`22
`(("TXD"(W)"258")/BI)
`"XRP"/BI
`120
`"XRPS'VBI
`1
`"XRP"/BI
`120
`(("XRP" OR "XRPS")/BI)
`195
`"6258"/BI
`44
`"XRP 6258"/BI
`(("XRP"(W)"6258")/BI)
`1345729-91-0/BI
`0
`1393818-87-5/BI
`0
`1402820-62-5/BI
`0
`1402820-63-6/BI
`0
`1402820-64-7/BI
`0
`1402820-65-8/BI
`0
`1402820-68-1/BI
`0
`1426815-65-7/BI
`0
`1426815-66-8/BI
`0
`1426815-67-9/BI
`0
`1430721-70-2/BI
`0
`1438897-79-0/BI
`0
`1443430-50-9/BI
`0
`460
`183133-96-2/BI
`890654-44-1/BI
`0
`849140
`7NEOPLAS?
`2149985
`7CANCER?
`2252686
`7TUMO?
`404392
`ONCO?
`1106224
`CARCIN?
`217585
`?SARCOMA?
`678
`L4 AND (7NEOPLAS? OR 7CANCER? OR 7TUMO?
`?SARCOMA?)
`=> s 112 and py<2011
`25095555 PY<2011
`80 L12 AND PY<2011
`L13
`=> s 113 and prostate
`216878 PROSTATE
`3880 PROSTATES
`216974 PROSTATE
`(PROSTATE OR PROSTATES)
`59 L13 AND PROSTATE
`
`L12
`
`OR
`
`ONCO?
`
`OR
`
`CARCIN?
`
`LI 4
`=> d his
`2013)
`(FILE 'HOME' ENTERED AT 10:55:45 ON 10 SEP
`FILE 'REGISTRY' ENTERED AT 10:55:54
`ON
`10 SEP
`2013
`1 S CABAZITAXEL/CN
`13 S 183133-96-2/CRN
`14 S LI OR L2
`SELECT CHEM L3 1-
`QUE E1-E20
`FILE 'HCAPLUS' ENTERED AT 10:56:37
`2013
`ON 10 SEP
`DEL SEL Y
`
`
`OR OR (TREAT? OR CURE THU)/RL
`245 S L4(L)((PAC OR PKT OR DMA
`OR BAC
`
`206 S L5 AND (?NEOPLAS? OR ?CANCER?
`
`OR ?TUMO? ONCO? OR CARCIN? O OR
`42 S L6 AND (AD<20101020 OR PD<20101020 OR PRD<20101020)
`
`LI
`L2
`L3
`L4
`
`L5
`L6
`L7
`
`01903
`
`

`
`L8
`L9
`
`LI 0
`LI 1
`
`
`
`
`
`FILE
`ENTERED AT 10:58:50 ON 10 SEP 2013
`
`'BIOSIS'
`(7NEOPLAS? OR 7CANCER? OR 7TUMO? OR ONCO? OR CARCIN? 0 125 S L4 AND
`
`PY<2 011
`10 S L8 AND
`'MEDLINE' ENTERED AT 10:59:12 ON 10 SEP FILE 2013
`
`DEL SEL Y
`
`236 S L4 AND (7NEOPLAS? OR 7CANCER? OR 7TUMO? OR ONCO? OR CARCIN? O
`22 S LI0 AND PY<2011
`'EMBASE' ENTERED AT 10:59:26 ON 10 FILE SEP 2013
`
`DEL SEL Y
`L12
`678 S L4 AND (?NEOPLAS? OR ?CANCER?
`80 S L12 AND PY<2011
`L13
`59 S L13 AND PROSTATE
`LI 4
`=> dup rem 17 19 111 114
`COST IN U.S. DOLLARS
`FULL ESTIMATED COST
`FILE 'HCAPLUS' ENTERED AT 11:00:06 ON 10 SEP 2013
`
`
`USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
`PLEASE SEE "HELP USAGETERMS" FOR
`DETAILS.
`COPYRIGHT (C) 2013 AMERICAN CHEMICAL SOCIETY
`(ACS)
`
`FILE 'BIOSIS' ENTERED AT 11:00:06 ON 10 SEP 2013
`Copyright (c) 2013 The Thomson Corporation
`
`FILE 'MEDLINE' ENTERED AT 11:00:06 ON 10 SEP 2013
`
`FILE 'EMBASE' ENTERED AT 11:00:06 ON 10 SEP 2013
`Copyright (c) 2013 Elsevier B.V.
`All
`
`rights reserved.
`PROCESSING COMPLETED FOR L7
`PROCESSING COMPLETED FOR L9
`PROCESSING COMPLETED FOR Lll
`PROCESSING COMPLETED FOR L14
`L15
`101 DUP REM L7 L9 Lll L14 (32 DUPLICATES REMOVED)
`=> d 115 1-101 ibib abs hitstr
`L15 ANSWER 1 OF 101
`HCAPLUS COPYRIGHT 2 013 ACS on STN
`ACCESSION NUMBER:
`2013:277129 HCAPLUS
`158:331494
`DOCUMENT NUMBER:
`Preparation of cyclodextrin-based polymers
`TITLE:
`therapeutic delivery as antitumor agents
`Crawford, Thomas C.; Fetzer, Oliver
`S.;
`INVENTOR(S):
`Lawrence Alan; Wolfgang, Marc
`Cerulean Pharma Inc., USA
`PATENT ASSIGNEE(S):
`PCT Int. Appl., 386pp.
`SOURCE:
`CODEN: PIXXD2
`DOCUMENT TYPE:
`Patent
`LANGUAGE:
`English
`
`FAMILY ACC. NUM. COUNT: 3
`PATENT INFORMATION:
`PATENT NO.
`DATE
`APPLICATION NO.
`KIND DATE
`20120730
`WO 2012-US48865
`20130221
`A1
`WO 2013025337
`W:
`
`AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR,
`CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
`EG, ES, FI, GB, GD, GE, GH,
`GM, GT, HN, HR, HU, ID, IL, IN, IS,
`JP, KE, KG, KM, KN, KP, KR,
`KZ, LA, LC, LK, LR, LS, LT, LU, LY,
`
`OR ?TUMO?
`
`OR
`
`ONCO?
`
`OR
`
`CARCIN?
`
`SINCE FILE
`ENTRY
`2.17
`
`TOTAL
`SESSION
`31.38
`
`for
`Reiter,
`
`01904
`
`

`
`MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
`PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL,
`SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
`VN, ZA, ZM, ZW
`
`RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
`HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
`SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
`MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD,
`SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM
`20110812 <—
`A1
`20120308
`US 2011-13208703
`US 20120058971
`A 20110812
`PRIORITY APPLN. INFO.:
`US 2011-13208703
`P 20091123 <—
`US 2009-61263749
`US 2010-61391922
`P 20101011 <—
`US 2010-953390
`A2 20101123
`AVAILABLE
`IN LSUS
`DISPLAY
`FORMAT
`
`ASSIGNMENT HISTORY FOR US PATENT
`GI
`
`CD
`
`S
`
`S
`
`NH
`
`L
`L
`D D
`
`O
`
`O
`
`NH— comonomer
`n
`
`I
`
`AB
`
`IT
`
`RN
`CN
`
`Methods and compns. relating to
`(CDP)-taxane
`polymers
`cyclodextrin-based
`each
`L is
`is
`cyclodextrin
`derivative;
`conjugates I, wherein CD ring
`a
`taxane,
`each
`D
`is
`independently
`independently a linker or absent;
`provided
`4,
`each comonomer comprises polyethylene
`glycol;
`n is
`at least
`that the CDP-taxane conjugate comprises
`selected
`from
`at least
`one
`taxane
`docetaxel, larotaxel, and cabazitaxel, to a subject in an amount effective
`
`to treat the cancer, are described herein. A method of selecting a
`subject having cancer, for treating the subject with a
`CDP-taxane
`conjugate was claimed, the
`method comprising:
`determining
`if
`cancer is at risk for or has diarrhea,
`proliferative
`disorder,
`treatment
`retention, hepatic impairment, severe
`neuropathy,
`from
`anticancer agent with a CDP-taxane conjugate.
`183133-96-2
`or reagent)
`RL: RCT (Reactant); RACT (Reactant
`(preparation of cyclodextrin-based polymers
`for
`delivery as antitumor agents)
`183133-96-2 HCAPLUS
`Benzenepropanoic acid, p-[[(1,1